Global X MSCI Argentina ETF vs Bristol-Myers Squibb Co — how do they compare? Global X MSCI Argentina ETF trades at $92.24, while Bristol-Myers Squibb Co trades at $63.88 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Global X MSCI Argentina ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X MSCI Argentina ETF nearer its low. Which is the better fit depends on your goals.
| ARGT | BMY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $65.89 |
52-Week Low | $67.55 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →